Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
British Journal of Haematology
|
July 30, 2015
Time to redefine Myeloma
Guy Pratt, Stella Bowcock, Andrew Chantry, et al.
Blood Advances
|
July 5, 2022
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
Charles Agbuduwe, Gulnaz Iqbal, David Cairns, et al.
Trials
|
March 9, 2018
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
Alina Striha, A John Ashcroft, Anna Hockaday, et al.
The Lancet. Haematology
|
November 18, 2017
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study
John P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
Blood
|
December 23, 2022
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial
Aikaterini Panopoulou, David A Cairns, Amy Holroyd, et al.
British Journal of Haematology
|
November 22, 2020
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial
Marquita Camilleri, Jonathan Sive, William Wilson, et al.
British Journal of Haematology
|
August 20, 2024
PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia
Jaimal Kothari, Toby Eyre, Ali Rismani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia
Meletios Athanasios Dimopoulos, Morie A Gertz, Efstathios Kastritis, et al.
Blood
|
August 23, 2017
Neutral tumor evolution in myeloma is associated with poor prognosis
David C Johnson, Oleg Lenive, Jonathan Mitchell, et al.
Clinical Lymphoma & Myeloma
|
April 28, 2006
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia
Eva Kimby, Steven P Treon, Athanasios Anagnostopoulos, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
British Journal of Haematology
|
July 30, 2015
Time to redefine Myeloma
Guy Pratt, Stella Bowcock, Andrew Chantry, et al.
Blood Advances
|
July 5, 2022
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
Charles Agbuduwe, Gulnaz Iqbal, David Cairns, et al.
Trials
|
March 9, 2018
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
Alina Striha, A John Ashcroft, Anna Hockaday, et al.
The Lancet. Haematology
|
November 18, 2017
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study
John P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
Blood
|
December 23, 2022
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial
Aikaterini Panopoulou, David A Cairns, Amy Holroyd, et al.
British Journal of Haematology
|
November 22, 2020
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial
Marquita Camilleri, Jonathan Sive, William Wilson, et al.
British Journal of Haematology
|
August 20, 2024
PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia
Jaimal Kothari, Toby Eyre, Ali Rismani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia
Meletios Athanasios Dimopoulos, Morie A Gertz, Efstathios Kastritis, et al.
Blood
|
August 23, 2017
Neutral tumor evolution in myeloma is associated with poor prognosis
David C Johnson, Oleg Lenive, Jonathan Mitchell, et al.
Clinical Lymphoma & Myeloma
|
April 28, 2006
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia
Eva Kimby, Steven P Treon, Athanasios Anagnostopoulos, et al.
Page
of 8